Aditxt (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing and deploying promising health innovations, has announced a new president for its majority-owned subsidiary, Pearsanta Inc. According to the announcement, Christoper Mitton has been named president of the subsidiary, which focuses on precision health. Mitton has an impressive career of leadership in the medical diagnostics space spanning more than two decades. His experience includes building and leading successful commercial operations, as well as gaining impressive expertise in product commercialization, business development, and strategic sales and marketing.
According to the announcement, Mitton will continue to serve as CEO of MDNA Life Sciences Inc. His previous experience has included heading sales operations at Cancer Genetics Inc., leading the North American commercial expansion for Ipsogen and managing the entire personalized healthcare portfolio for Qiagen.
“We are thrilled to welcome Chris to Pearsanta at this pivotal moment,” said Aditxt cofounder, chair and CEO Amro Albanna in the press release. “Our mission at Aditxt is to build and accelerate companies focusing on innovative health solutions that tackle some of the most critical challenges in healthcare. We believe that Chris’s leadership will be key as we seek to drive the commercial success of Pearsanta, advancing breakthrough innovations and creating value for all stakeholders. We feel strongly that his personalized healthcare and commercial strategy expertise make him the ideal leader to guide Pearsanta’s next growth phase as we accelerate our precision health initiatives.”
To view the full press release, visit https://ibn.fm/eedw8
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
